Veristat

Veristat, Inc. is a clinical research organization based in Southborough, Massachusetts, with additional offices in North Carolina, California, Canada, the United Kingdom, and Taiwan. Established in 1994, the company specializes in providing a range of clinical development services to pharmaceutical, biotechnology, and medical device companies. These services include biostatistics, statistical programming, medical writing, clinical monitoring, project management, and data management. Veristat supports clients through various stages of clinical trials, offering solutions for advanced study designs, predictive modeling, and regulatory submissions. The firm is dedicated to scientific integrity and client focus, fostering long-lasting relationships with a diverse clientele engaged in developing new pharmaceutical products, vaccines, and medical devices.

Patrick Flanagan

CEO and Chairman

5 past transactions

Instat Clinical Research

Acquisition in 2023
Instat Clinical Research specializes in clinical data management and medical writing services, supporting all phases of clinical development. The company offers a range of services, including design and analysis for clinical trials, statistical analysis, and consultancy. Additionally, Instat provides electronic health record management and advisory services, enabling clients to make informed decisions through detailed reports and annual subscriptions. With a focus on delivering comprehensive solutions, Instat aims to enhance the efficiency and effectiveness of clinical research processes.

Scinopsis

Acquisition in 2023
Scinopsis is a medical writing consultancy that specializes in providing comprehensive documentation services for the pharmaceutical, biotechnology, and medical device industries. The company offers expertise in medical documentation consulting across various therapeutic areas, including aesthetics, anesthesia, cardiovascular disorders, cell therapy, clinical pharmacology, and gastroenterology. Scinopsis employs qualified scientists and medical experts to ensure the quality and accuracy of its services, which include the preparation and filing of clinical trial and regulatory documents. Through its specialized knowledge, Scinopsis aids clients in navigating the complex regulatory landscape, enhancing their ability to communicate critical information effectively.

SFL Regulatory Affairs & Scientific Communication

Acquisition in 2022
SFL is a leading consultancy providing integrated solutions to pharma, biotech and medtech companies for global and local activities. SFL’s combined in-house expertise and services mirror key functions in a pharma or medtech product’s life cycle: Regulatory Affairs & Regulatory Intelligence, Quality & Supply Chain, Medical Writing, Public Affairs & Reimbursement/Market Access, Pharmacovigilance, and Compliance. Apart from strategic and operational support of client projects, experienced SFL team members can take over company-internal roles on an interim management base and provide training courses. In addition, SFL has a Swissmedic establishment license, SME-status at EMA and a network of agents in US, Japan, Canada and other countries. Therefore, SFL can act as marketing authorization applicant and MAH in Switzerland and the EU and conduct submissions to FDA, PMDA and Health Canada and other authorities.

SQN Clinical

Acquisition in 2021
SQN Clinical is a specialist biometrics CROs in Europe and is the preferred clinical development partner for many pharmaceutical, biotechnology and animal healthcare companies in the UK, Europe and the rest of world.

Spero Oncology

Acquisition in 2016
Spero Oncology is a clinical research organization specializing in the development of oncology products. The company offers clinical operations support for oncology clinical trials, with a primary focus on Europe, as well as operations in Australia and New Zealand.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.